Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.57 |
| ▸ | VEGFA | P15692 | 4/20 | 0.57 |
| ▸ | FLT1 | P17948 | 4/20 | 0.57 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.57 |
| ▸ | TET3 | O43151 | 1/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.48 |
| ▸ | ASPH | Q12797 | 1/20 | 0.48 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.48 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.48 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.48 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.48 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34467363 | 1.00 | EGLN1 (0.57) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL34467306 | 0.91 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL23501771 | 0.91 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30452288 | 0.83 | VEGFA (0.47) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL29188896 | 0.82 | EGLN1 (0.75) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL3484916 | 0.80 | EGLN1 (0.82) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL24579666 | 0.80 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30790421 | 0.80 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30957053 | 0.76 | EGLN1 (0.72) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL26170222 | 0.76 | EGLN1 (0.72) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | AKEBIA THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| WO-2021117767-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | 田辺三菱製薬株式会社 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | DIMT1, HIF1A, HIF1AN | EGLN1 912/4885VEGFA 269/4885FLT1 2371/4885 |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | DIMT1, DLAT, COASY | EGLN1 1247/4885VEGFA 747/4885FLT1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.